Research programme: anti-infective vaccines - TVAX Biomedical

Drug Profile

Research programme: anti-infective vaccines - TVAX Biomedical

Alternative Names: TVI-Hepatitis-1; TVI-HIV-1; TVI-Tuberculosis-1

Latest Information Update: 09 Jan 2013

Price : $50

At a glance

  • Originator TVAX Biomedical
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Hepatitis; HIV infections; Tuberculosis

Most Recent Events

  • 09 Jan 2013 Preclinical development is ongoing USA
  • 08 Jun 2011 Preclinical trials in Tuberculosis in USA (IV)
  • 08 Jun 2011 Preclinical trials in Hepatitis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top